Comparative Pharmacology
Head-to-head clinical analysis: ACETAZOLAMIDE versus DIAMOX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ACETAZOLAMIDE versus DIAMOX.
ACETAZOLAMIDE vs DIAMOX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Reversible inhibition of carbonic anhydrase, primarily in the proximal renal tubule, reducing hydrogen ion secretion and increasing bicarbonate, sodium, potassium, and water excretion. Also reduces aqueous humor formation via ocular carbonic anhydrase inhibition.
Carbonic anhydrase inhibitor; decreases aqueous humor production by inhibiting carbonic anhydrase in ciliary processes, leading to reduced intraocular pressure. Also inhibits carbonic anhydrase in renal tubules, causing bicarbonate diuresis and metabolic acidosis.
250-500 mg orally twice daily or 250 mg intravenously twice daily; for edema, 250-375 mg orally once daily; for altitude sickness, 250 mg orally every 8-12 hours.
250 mg orally every 6-8 hours for glaucoma; 250-375 mg orally once daily for altitude sickness; 5 mg/kg IV or IM every 6 hours for edema in congestive heart failure
None Documented
None Documented
Clinical Note
moderateAcetazolamide + Atorvastatin
"The risk or severity of adverse effects can be increased when Acetazolamide is combined with Atorvastatin."
Clinical Note
moderateAcetazolamide + Diclofenamide
"The risk or severity of adverse effects can be increased when Acetazolamide is combined with Diclofenamide."
Clinical Note
moderateAcetazolamide + Fosphenytoin
"The risk or severity of adverse effects can be increased when Acetazolamide is combined with Fosphenytoin."
Clinical Note
moderateTerminal half-life approximately 10–15 hours; prolonged in renal impairment (up to 30+ hours).
10-15 hours; prolonged to up to 24+ hours in renal impairment; clinical context: requires twice-daily dosing for continuous effect.
Renal: ~90% unchanged drug via tubular secretion and glomerular filtration; minor biliary/fecal (<2%).
Renal; 70-100% unchanged by tubular secretion and passive reabsorption; pH-dependent; alkaline urine increases elimination.
Category C
Category C
Carbonic Anhydrase Inhibitor
Carbonic Anhydrase Inhibitor
Acetazolamide + Phenytoin
"The risk or severity of adverse effects can be increased when Acetazolamide is combined with Phenytoin."